Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BIOC

BIOC - Biocept Inc Stock Price, Fair Value and News

$0.43 
Market Closed

BIOC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BIOC Price Action

BIOC RSI Chart

BIOC Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BIOC Valuation

BIOC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BIOC Fundamentals

BIOC Revenue

BIOC Earnings

BIOC Profitability

BIOC Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
202263.4M57.2M40.7M25.9M
202143.8M54.9M65.8M61.2M
20206.0M5.7M10.7M27.5M
20193.5M3.8M4.6M5.5M
20184.2M3.7M3.4M3.3M
20174.7M5.3M5.4M5.1M
2016681.3K1.3M2.1M3.2M
2015223.0K312.7K467.2K609.9K
2014134.1K133.9K133.6K133.4K
2013134.1K128.4K136.4K134.2K
2012000109.3K
Get all data in R, Python etc through our Historical Stock Data APIs

About Biocept Inc

BIOC
Biocept, Inc., a molecular oncology diagnostics company, develops and commercializes proprietary clinical diagnostic laboratory assays designed to identify rare tumor cells and cell-free tumor DNA from blood and cerebrospinal fluid, or CSF in the United States. Its cancer assays provide information to healthcare providers to identify oncogenic alterations that qualify a subset of cancer patients for targeted therapy at diagnosis, progression, and monitoring to identify resistance mechanisms. The company offers assays for solid tumor indications, such as breast cancer, non-small cell lung cancer (NSCLC), gastric cancer, colorectal cancer, prostate cancer, pancreaticobiliary cancer, and ovarian cancer. It also provides cerebrospinal fluid tumor cell and ctDNA and ctRNA testing services to medical oncologists, neuro-oncologists, surgical oncologists, radiation oncologists, urologists, pulmonologists, pathologists, and other physicians; and clinical trial and research services to pharmaceutical companies, biopharmaceutical companies and clinical research organizations. The company has a collaboration with CLEARED4 to develop a system for tracking and managing COVID-19 testing requirements and test results for its customers; and with Protean BioDiagnostics, Inc. to research the ability of its Target Selector molecular assay to determine EGFR status in NSCLC patients. Biocept, Inc. was incorporated in 1997 and is headquartered in San Diego, California.
 CEO
 WEBSITEhttps://biocept.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES50